Pfizer Doses First Patient In Phase 2/3 Trial For Daily COVID Pill
By Tyler Durden Pfizer revealed on Wednesday that it had finally dosed its first patient participating in the Phase 2/3 study examining the efficacy of PF-07321332, an orally administered protease inhibitor antiviral designed to combat COVID-19. The randomized, double-blind trial will enroll approximately 1,140 participants,…
